Sanofi (SNY) trades at a trailing P/E of 9.2, forward P/E of 11.3. Trailing earnings yield is 10.86%, forward earnings yield 8.88%. PEG 0.10 (Peter Lynch undervalued ≤1.0). Graham Number is $107.24.
Criteria proven by this page:
Overall SharesGrow Score: 75/100 with 5/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 21.0 | 1.81 | 1.72 | 2.85 | 3.80% |
| 2017 | 10.7 | -0.59 | 1.55 | 2.49 | 4.12% |
| 2018 | 21.9 | 1.46 | 1.60 | 2.65 | 4.00% |
| 2019 | 40.6 | -1.20 | 1.90 | 2.97 | 3.43% |
| 2020 | 8.1 | 0.02 | 1.58 | 2.67 | 3.95% |
| 2021 | 17.7 | -0.36 | 1.61 | 2.82 | 3.63% |
| 2022 | 13.5 | 0.48 | 1.51 | 2.79 | 3.68% |
| 2023 | 21.0 | -0.65 | 1.53 | 2.72 | 3.93% |
| 2024 | 21.0 | 11.30 | 1.50 | 2.63 | 4.04% |
| 2025 | 12.9 | -1.66 | 1.41 | 2.15 | 4.55% |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $1.83 | $34.7B | $4.71B | 13.6% |
| 2017 | $3.36 | $36.22B | $3.89B | 10.8% |
| 2018 | $1.73 | $35.68B | $4.31B | 12.1% |
| 2019 | $1.12 | $37.63B | $2.81B | 7.5% |
| 2020 | $4.91 | $37.37B | $12.29B | 32.9% |
| 2021 | $2.49 | $39.18B | $6.22B | 15.9% |
| 2022 | $2.69 | $45.39B | $8.37B | 18.4% |
| 2023 | $2.15 | $46.03B | $5.4B | 11.7% |
| 2024 | $2.30 | $44.29B | $5.56B | 12.6% |
| 2025 | $2.03 | $46.72B | $7.81B | 16.7% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $4.23 | $4.15 – $4.38 | $47.98B | $45.53B – $52.13B | 6 |
| 2027 | $4.51 | $4.34 – $4.63 | $51.03B | $48.39B – $55.42B | 6 |
| 2028 | $4.93 | $4.66 – $5.38 | $53.34B | $51.13B – $57.06B | 3 |
| 2029 | $5.45 | $5.16 – $5.95 | $55.75B | $53.45B – $59.65B | 4 |
| 2030 | $5.98 | $5.65 – $6.52 | $57.89B | $55.5B – $61.94B | 2 |
